roche holding ag frances transgene sets cancer vaccine deal roche holding ag signed a deal valued at as much as million euros &# million with french biotechnology company transgene sa to develop and sell vaccines against cervical cancer the deal gives switzerland based roche access to transgenes therapeutic vaccine program against cervical cancer and other human papilloma virus mediated diseases transgenes lead product a therapeutic vaccine candidate known as tg is in midstage testing and could enter the market as early as if it succeeds in the third and final phase of clinical testing analysts say roche will pay transgene million euros upfront and a further million euros if certain regulatory milestones are reached 
